Free Trial
NASDAQ:APLT

Applied Therapeutics Q1 2024 Earnings Report

Applied Therapeutics logo
$0.49 -0.02 (-3.64%)
Closing price 04:00 PM Eastern
Extended Trading
$0.50 +0.01 (+1.48%)
As of 07:39 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

Applied Therapeutics EPS Results

Actual EPS
-$0.16
Consensus EPS
-$0.07
Beat/Miss
Missed by -$0.09
One Year Ago EPS
N/A

Applied Therapeutics Revenue Results

Actual Revenue
$0.19 million
Expected Revenue
$10.00 million
Beat/Miss
Missed by -$9.81 million
YoY Revenue Growth
N/A

Applied Therapeutics Announcement Details

Quarter
Q1 2024
Time
N/A
Conference Call Date
Thursday, May 9, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Applied Therapeutics' Q3 2025 earnings is scheduled for Thursday, November 6, 2025, with a conference call scheduled on Monday, November 10, 2025 at 4:00 PM ET. Check back for transcripts, audio, and key financial metrics as they become available.

Applied Therapeutics Earnings Headlines

Q3 Earnings Estimate for APLT Issued By Leerink Partnrs
Altucher: It Looks Like My Trump prediction is coming true
New Hampshire just launched a Strategic Crypto Reserve — and James Altucher says it’s the first sign that “Trump’s Great Gain” has officially begun. Altucher believes select cryptos could turn $900 into $108,000 over the next 12 months — and he’s laying out the full gameplan in a new presentation.tc pixel
Applied Therapeutics Reports Q2 Loss
See More Applied Therapeutics Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Applied Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Applied Therapeutics and other key companies, straight to your email.

About Applied Therapeutics

Applied Therapeutics (NASDAQ:APLT), Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The company's lead product candidate is AT-007 (also called govorestat) that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It also develops AT-001 (also called caficrestat) that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York.

View Applied Therapeutics Profile

More Earnings Resources from MarketBeat